FLEXDOSE® launches in the USA – PCCA and DiHeSys present innovative printing technology for personalized medicine
- dihesys
- Oct 13
- 1 min read
Houston, Texas / Schwäbisch Gmünd
At the annual congress of the PCCA (Professional Compounding Centers of America), PCCA and DiHeSys jointly presented the FLEXDOSE® Printer for individualized pharmaceuticals for the first time.
Around 400 participants from the compounding pharmacy sector were impressed, interested, and in some cases amazed by the system's technological capabilities. Many said they hadn't expected such a solution for another ten years—a sign of DiHeSys's innovative edge.
Gus Bassani, CEO of PCCA, and Holger Reinhoff, CEO of DiHeSys GmbH, were enthusiastic about the strong interest and positive response.
"Demand for our system has been overwhelming. FLEXDOSE® sets new standards in quality, efficiency, and user-friendliness."
With its launch in the USA, DiHeSys is setting another milestone on the path to digital, personalized drug manufacturing – and underscoring its role as a technological pioneer in the field of 2D/3D printing of personalized medicine.
